Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Closes PanVera Acquisition

NEW YORK, March 31 - Invitrogen has completed its acquisition of Vertex Pharmaceuticals subsidiary PanVera, the companies said today.


The $95 million cash deal, first announced in early February, will add PanVera's biochemical and cellular assay capabilities as well as proprietary reagents, probes, and proteins to Invitrogen's product portfolio.


Invitrogen is also acquiring PanVera's new R&D and manufacturing facility in Madison, Wis., where more than 100 PanVera employees are currently headquartered.


Invitrogen said it plans to expand the sale of PanVera products to target a broader market, including academic and government researchers.


Vertex Pharmaceuticals acquired the PanVera as part of its acquisition of Aurora Biosciences in July 2001.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.